Recent patent applications in biomarkers

Patent number	Description	Assignee	Inventor	Priority application date	Publication date
WO 2009080779	A method of diagnosing psoriasis in a patient comprising detecting the expression of the carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) gene in a biological sample obtained from the patient.	INSERM (Paris)	Moles J, Pene J, Yssel H	12/20/2007	7/2/2009
WO 2009077763	Diagnosing or monitoring a psychotic disorder or predisposition to it, comprising measuring in a sample taken from a subject the level of first peptide biomarkers, e.g., anti-nuclear antibody, and early antigen erythropoietin.	Cambridge Enterprise (Cambridge, UK), Psynova Neurotech (Cambridge, UK)	Bahn S, Levin Y, McAllister G, Schwarz E, Wang L	12/19/2007	6/25/2009
WO 2009078806	A biomarker identifying a method for assessing, e.g., skeletal muscle function, involving identifying a protein or ortholog, fragment, degradation product, splice variant or allelic variant, whose presence and amount are correlated to function.	Fraengsmyr LC, Malm BC	Fraengsmyr LC, Malm BC	12/19/2007	6/25/2009
WO 2009075566	A method of diagnosis or prognosis of cardiovascular disease comprising detecting the presence of activated endothelial progenitor cells (EPC) in a sample of a circulation fluid.	Erasmus University Medical Center (Rotterdam, The Netherlands)	Duckers HJ	12/12/2007	6/18/2009
WO 2009074350, EP 2071336	A new biomarker that is regulated by epidermal growth factor (EGF) overexpression in a subject; useful for identifying drugs against cancer associated with an increased EGF receptor (EGFR) kinase activity.	Fraunhofer-Gesellschaft (Munich)	Borlak J, Gazzana G	12/13/2007	6/18/2009, 6/17/2009
WO 2009075795	A method of predicting tumor response to treatment in a non-Hodgkin's lymphoma patient comprising obtaining tumor cells from the patient, culturing the cells in the presence or absence of a quinazolinone compound, and measuring SPARC expression in the tumor cells.	Celgene (Summit, NJ, USA)	Bartlett JB, Schafer PH, Zhang L	12/7/2007	6/18/2009
WO 2009075883	A method of evaluating the presence, absence, nature or extent of cancer or a precancerous condition comprising detecting the presence of a cancer-specific glycoform of a glycoprotein in a biological sample obtained from the subject, where the cancer-specific glycoform comprises a glycan indicative of the presence of cancer or a precancerous condition.	University of Georgia Research Foundation (Athens, GA, USA)	Abbott KL, Pierce MJ	12/12/2007	6/18/2009
WO 2009076472, US 20090155804	Identifying a responder patient population for treatment with an exogenous agent, by establishing a cellular model of disease space based on one or more signaling pathways; identifying the effect of the exogenous agent in the signaling pathway; determining a biomarker responder package including a set of biomarkers; assaying the state of the signaling pathway with the biomarker responder package before and after drug dosing; and identifying the responder patient population that will be responsive for the exogenous agent based on the assay.	Blume-Jensen P	Blume-Jensen P	12/12/2007	6/18/2009
JP 2009121874	Diagnosing digestive system cancer, e.g., colon cancer, involving detecting human dermokine-beta peptide in a blood sample and determining the presence or absence of digestive cancer based on the variation in the level of biomarkers.	Eisai R&D Management Co. (Tokyo)	Ida Y, Kikuchi S, Kisumi F, Matsui T, Ochiai T, Suzuki S,Tagi T	11/13/2007	6/4/2009
KR 2009017230	Biomarkers useful for diagnosing exposure to formaldehyde and determining the risk of formaldehyde in environment and real life, including genes such as S100 calcium binding protein A9 (calgranulin B) gene and cytochrome c-1 gene.	Korea Institute of Science & Technology (Seoul)	Kim Y, Nath Sarma S, Ryu JC	8/14/2007	2/18/2009

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).